Moreover, the majority of ERBB2-positive gastric cancers do not respond to trastuzumab therapy, indicating that inhibition of ERBB2 signaling alone is either ineffective or only transiently effective.40 Our observations show that multiple signaling pathways operate in parallel in gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.